Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. November 2020 08:30 ET | Quelle: ARCA biopharma, Inc.

AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation

Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or notAB201 is the only novel compound being developed for COVID Associated...
02. November 2020 08:30 ET | Quelle: ARCA biopharma, Inc.

ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update

Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID19 anticipated in fourth quarterTopline data from trial anticipated Q2 2021 WESTMINSTER, Colo., Nov. 02,...
07. Oktober 2020 08:30 ET | Quelle: ARCA biopharma, Inc.

ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19

Initiation of Phase 2b clinical trial anticipated in Q4 2020Trial to enroll approximately 100 patients hospitalized with COVID-19Topline data anticipated Q2 2021 WESTMINSTER, Colo., Oct. 07, 2020 ...
21. September 2020 08:00 ET | Quelle: ARCA biopharma, Inc.

ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19

WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...